ASCO Meeting Abstracts -- Cascinu et al. 25 (18 Supplement): 4544 Table 1

	GEM/CDDP	plus CETUXIMAB

Treatment cycles (median, range)
PR (95%CI)	3 (8%)	6 (16%)
PR+SD (95%CI)	20 (54%)	28 (75%)
TTP (median, months)	5	5
Grade 3–4 toxicities	31%	29%